Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project.

Autor:	Gori S; Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. Electronic address: stefania.gori@sacroccuore.it., De Rose F; Radiation Oncology, APSS, Trento, Italy., Ferro A; Oncologia Medica, Breast Unit APSS, Trento, Italy., Fabi A; Head of Precision Medicine Unit in Senology, Responsabile UOSD Medicina di Precisione in Senologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli, 8, 00168 Roma, Italy., Angiolini C; Breast Medical Oncology, Oncology Department, Careggi Hospital, Firenze, Italy., Azzarello G; Unità Operativa Complessa Oncologia, AULSS 3 Serenissima, Mirano-Dolo (Venezia), Italy., Cancian M; General Practitioner, Coordinatore MGI De Gironcoli, Conegliano, Treviso, Italy; National Executive Council of the Italian Society of General Medicine (S.I.M.G.), Florence, Italy., Cinquini M; Laboratorio di metodologia delle revisioni sistematiche e produzione di linee guida, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Arecco L; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy; Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Aristei C; Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Italy., Bernardi D; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano - Milan, Italy., Biganzoli L; Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy., Cariello A; Oncologia di Ravenna-AUSL Romagna, Ravenna, Italy., Cortesi L; Oncologia, Ematologia e Malattie dell'apparato respiratorio, Azienda Ospedaliera-Universitaria, Policlinico di Modena, Italy., Cretella E; Oncologia Medica, Ospedale di Bolzano, Italy., Criscitiello C; Sviluppo Nuovi farmaci per le terapie innovative, Istituto Europeo di Oncologia (IEO) IRCCS, Università degli studi di Milano, Milano, Italy., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola FC, Italy., Carmen De Santis M; Radiation Oncology Fondazione I.R.C.C.S. Istituto Nazionale Tumori di Milano, Italy., Deledda G; Clinical Psychology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy., Dessena M; S.S. Senologia Chirurgica, Chirurgia Polispecialistica, Policlinico Universitario di Monserrato, Azienda Ospedaliera Universitaria, Cagliari, Italy., Donati S; Oncologia Ospedale Versilia, Camaiore, Lucca, Italy., Dri A; Dipartimento di Oncologia Medica - Centro di Riferimento Oncologico (CRO) - IRCCS Aviano, Pordenone, Università degli Studi di Udine, Italy., Ferretti G; Divisione Oncologia Medica 1, IRCCS Regina Elena National Cancer Institute, Roma, Italy., Foglietta J; Oncologia Medica e Traslazionale, Ospedale Santa Maria di Terni, Italy., Franceschini D; Department of Radiotherapy and Radiosurgery, IRCCS - Humanitas Research Hospital, Rozzano, Milano, Italy., Franco P; Department of Translational Medicine (DIMET), University of Eastern Piedmont, Novara, Italy; Department of Radiation Oncology, 'Maggiore della Carità' University Hospital, Novara, Italy., Schirone A; Unità Operativa Interaziendale di Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Italy., Generali D; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste, Italy., Gianni L; UO Operativa di Oncologia-Ospedale Infermi, Rimini, Italy., Giordani S; Oncologia Territoriale - AUSL, Bologna, Italy., Grandi G; Associate Professor in Obstetrics and Gynecology, Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico, Via del Pozzo 71, 41124 Modena, Italy., Cristina Leonardi M; Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy., Magno S; UOS Terapie integrate in Senologia, Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma, Italy., Malorni L; S.O.S. Ricerca Traslazionale, S.O.C. Oncologia Medica, Nuovo Ospedale di Prato Santo Stefano, Azienda USL Toscana Centro, Prato, Italy., Mantoan C; Dirigente delle Professioni Sanitarie - Ospedale Fracastoro - San Bonifacio, Azienda Ulss9 Scaligera, Verona, Italy., Martorana F; Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Italy., Meattini I; Department of Experimental and Clinical Biomedical Sciences 'M. Serio' - University of Florence, Italy; Breast Unit & Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Meduri B; Department of Radiation Oncology, University Hospital of Modena, Modena, Italy., Merlini L; UOC Oncologia, Ospedali Riuniti Padova Sud, Azienda ULSS 6 Euganea, Italy., Miglietta F; Oncologia Medica 2, IRCCS Istituto Oncologico Veneto, DiSCOG Università degli Studi di Padova, Padova, Italy., Modena A; Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy., Nicolis F; Medical Direction, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy., Palumbo I; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano - Milan, Italy., Panizza P; Breast Imaging Unit, IRCCS Ospedale San Raffaele, Milano, Italy., Angela Rovera F; S.S.D. Breast Unit, ASST Sette Laghi - Università degli Studi dell'Insubria, Varese, Italy., Salvini P; Responsabile Medicina Oncologica, Policlinico Ponte S Pietro di Istituti Ospedalieri Bergamaschi, Ponte San Pietro, Bergamo, Italy., Santoro A; Humanitas Cancer Center - Istituto Clinico Humanitas IRCCS - Humanitas University - Rozzano, Milano, Italy., Taffurelli M; IRCCS Policlinico sant'Orsola, Università di Bologna, Italy., Toss A; Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy., Tralongo P; Struttura Complessa di Oncologia, Dipartimento di Oncologia, Ospedale Umberto I Siracusa, Italy., Turazza M; Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy., Valerio M; Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy., Verzè M; Medical Direction, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy., Vici P; UOSD Sperimentazioni Fase IV, IRCCS Istituto Nazionale Tumori Regina Elena, 00144 Rome, Italy., Zamagni C; Head Breast & Gynecological Medical Oncology Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Italy., Curigliano G; Istituto Europeo di Oncologia, IRCCS, Milano, Italy; Dipartimento di Oncologia ed Emato-Oncologia, Università di Milano, Milano, Italy., Pappagallo G; Methodology School of Clinical Research, IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy., Zambelli A; Medical Oncology Unity, IRCCS Istituto Clinico Humanitas and Department of Biomedical Sciences Humanitas University, Milano, Rozzano.
Jazyk:	angličtina
Zdroj:	Cancer treatment reviews [Cancer Treat Rev] 2024 Dec; Vol. 131, pp. 102832. Date of Electronic Publication: 2024 Oct 05.
DOI:	10.1016/j.ctrv.2024.102832
Abstrakt:	Breast cancer stands as the most frequently diagnosed cancer and the primary cause of cancer-related mortality among women worldwide, including Italy. With the increasing number of survivors, many are enrolled in regular follow-up programs. However, adherence to recommendations from scientific societies (such as ASCO, ESMO, AIOM) for breast cancer follow-up management varies in daily clinical practice across different cancer centers, potentially resulting in unequal management and escalating costs. To address these concerns, the Italian Association of Multidisciplinary Oncology Groups (AIGOM) orchestrated a Consensus on early Breast Cancer follow-up utilizing the Estimate-Talk-Estimate methodology. Following the identification of 18 Items and 38 statements by a select Board, 46 out of 54 (85.1%) experts comprising a multidisciplinary and multiprofessional panel expressed their degree of consensus (Expert Panel). The Expert Panel underscores the potential for the multidisciplinary team to tailor follow-up intensity based on the individual risk of recurrence. In selected cases, the general practitioner may be recommended as the clinical lead for breast cancer follow-up, both after completion of adjuvant treatment and at early initiation of endocrine therapy in low-risk patients. Throughout follow-up, and alongside oncologic surveillance, the expert panel advises osteometabolic, cardiologic, and gynecologic surveillance for the early detection and management of early and late treatment toxicities. Moreover, preserving quality of life is emphasized, with provisions for psycho-oncologic support and encouragement to adopt protective lifestyle behaviors. Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: None of the authors has any interests to report directly related to this manuscript. Outside the scope of this manuscript: Stefania Gori, Fiorenza De Rose, no conflict of interests to declare. Antonella Ferro, honoraria from Novartis, MDS, Daiichi Sankyo, Astra Zeneca, Ely Lilly, Gentili. Alessandra Fabi grants from Astra Zeneca (steering committee); consulting fees from Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Menarini; honoraria from Astra Zeneca, Roche, Lilly, Novartis, Gilead, Pfizer, Daiichi Sankyo Exact Sciences; travel grants from Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Menarini; advisory board from Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Menarini. Catia Angiolini, Giuseppe Azzarello, Maurizio Cancian, Michela Cinquini, Luca Arecco no conflict of interests to declare. Cynthia Aristei, grants from PRIN 2023, from the Ministry of University and Research. Project title “The microbiome in breast cancer therapy and its potential for pRobIOtics to improve treatment outcome. Acronym: BARRIO”. Daniela Bernardi, Laura Biganzoli, Anna Cariello no conflict of interests to declare. Laura Cortesi, report grants from Astra Zeneca, MSD, Pfizer; consulting fees and honoraria from Astra Zeneca, Gilead, MSD, Roche, Pfizer, Daijchii Sanchio, Novartis; travel grants from Gilead, Pfizer, Daijchi Sanchio; Advisory Board from Astra Zeneca, MSD, Novartis. Elisabetta Cretella no conflict of interests to declare. Carmen Criscitiello, grants from Seagen, Gilead; consulting fees and honoraria from Pfizer, Novartis, Lilly, MSD; Seagen, Daiichi Sankyo, Gilead, AstraZeneca, Roche. Ugo De Giorgi consulting fees from Amgen, Astellas Pharma, Astrazeneca, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen, Merck KGaA, MSD, Novartis, Pfizer; travel grants from Pfizer, Ipsen, Astrazeneca. Maria Carmen De Santis, Giuseppe Deledda, Massimo Dessena, Sara Donati, Arianna Dri, Gianluigi Ferretti no conflict of interests to declare. Jennifer Foglietta, honoraria from Novartis; travel grants from Roche, Sophos, Pfizer; Advisory Board from Menarini Stem Line. Davide Franceschini, Pierfrancesco Franco, Alessio Schirone no conflict of interests to declare. Daniele Generali, grants from LILT, University of Trieste, Novartis, Roche; consulting fees from Lilly, Novartis, Pfizer, Roche, Accord, Daiichi Dankyo; honoraria from Lilly, Novartis, Pfizer, Roche, Accord, Daiichi Dankyo, Astrazeneca, Istituto Gentili; travel grants from Roche, Menarini; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from Mednote. Lorenzo Gianni, travel grants from Novartis, Lilly, Pfizer; Advisory Board from Astra Zeneca, Novartis, Seagen. Stefano Giordani, Giovanni Grandi, Maria Cristina Leonardi, Stefano Magno, no conflict of interests to declare. Luca Malorni, consulting fees from Menarini, Pfizer, Lilly, Novartis, Roche; travel grants from Roche, Menarini, Celgene, IT Health Fusion; Advisory Board from Novartis. Carlotta Mantoan no conflict of interests to declare. Federica Martorana honoraria from Lilly, Daychii-Sankyo, Pfizer, Astra-Zeneca, Novartis; travel grants from Gilead, Roche, Pfizer, Lilly; advisory board from Amgen. Icro Meattini consulting fees from Pfizer, Astra Zeneca, Daiichi Sankyo, Novartis, Eli Lilly, Seagen, Gilead, Menarini StemLine. Bruno Meduri, Laura Merlini, Federica Miglietta, Alessandra Modena, Fabrizio Nicolis, Isabella Palumbo, no conflict of interests to declare. Pietro Panizza honoraria and travel grants from Bayer AG. Francesca Angela Rovera, Piermario Salvini, Armando Santoro, Mario Taffurelli, no conflict of interests to declare. Angela Toss consulting fees and grants from Lilly, Pfizer, Novartis, MSD, Astrazeneca, Gilead, Seagen, Daiichi Sankyo; travel grants from Gilead, Daiichi Sankyo, Menarini, Astrazeneca. Paolo Tralongo, Monica Turazza, Matteo Valerio, Matteo Verzè no conflict of interests to declare. Patrizia Vici consulting fees from Lilly, Daiichi-Sankyo, Pfizer, MSD, Novartis; honoraria from EISAI, Daiichi-Sankyo, Lilly, Novartis, Pfizer; travel grants from Roche, Pfizer, Daiichi-Sankyo, Novartis, IPSEN; advisory board from Pfizer, Novartis. Claudio Zamagni no conflict of interests to declare. Giuseppe Curigliano advisory board from Roche, Novartis, Lilly, Pfizer, Astra Zeneca, Daichii Sankyo, Ellipsis, Veracyte, Exact Science, Celcuity, Merck, BMS, Gilead, Sanofi, Menarini. Giovanni Pappagallo no conflict of interests to declare. Alberto Zambelli consulting fees Pfizer, Lilly, Novartis, Roche, AstraZeneca, DaiichiSankyo, Seagen, ExactSciences, MSD, Gentili, Gilead; travel grants from Roche, DaiichiSankyo, AstraZeneca, Novartis; advisory board from Roche. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect